Rapport Therapeutics (NASDAQ:RAPP) Shares Down 8.5% – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP) dropped 8.5% on Tuesday . The company traded as low as $14.66 and last traded at $14.55. Approximately 28,413 shares traded hands during trading, a decline of 71% from the average daily volume of 96,459 shares. The stock had previously closed at $15.90.

Rapport Therapeutics Stock Performance

The business has a 50 day moving average of $16.48 and a two-hundred day moving average of $20.00.

Institutional Investors Weigh In On Rapport Therapeutics

A number of hedge funds have recently made changes to their positions in RAPP. Deutsche Bank AG purchased a new stake in Rapport Therapeutics in the fourth quarter valued at about $41,000. Crestline Management LP purchased a new stake in Rapport Therapeutics in the fourth quarter valued at about $488,000. Virtus ETF Advisers LLC purchased a new stake in Rapport Therapeutics in the fourth quarter valued at about $66,000. Price T Rowe Associates Inc. MD raised its stake in Rapport Therapeutics by 9.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock valued at $20,285,000 after buying an additional 95,976 shares during the last quarter. Finally, TRV GP V LLC purchased a new stake in Rapport Therapeutics in the fourth quarter valued at about $126,579,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.